Skip to NavigationSkip to content

Nasal Spray

Ena Respiratory's nasal spray reduces COVID-19 replication by 96%

Australian biotech Ena Respiratory has revealed that its self-administered nasal spray INNA-051, when taken once or twice weekly, reduced viral replication of SARS-CoV-2 by up to 96%, according to one animal study conducted by Public Health England (PHE), and a second study investigating the treatment in rhinovirus infection in human airway cells.

The therapy works by activating epithelial cells in the body’s airways to boost immune response at the primary site of infection, which was shown in studies to “dramatically” reduce infection and replication rates of COVID-19 in animals.<

Drug-free nasal spray could prevent COVID-19 infection, promising data show

Auris Medical has revealed promising new in vitro data for AM-301, its drug-free nasal spray, showing that the product could potentially protect from COVID-19.  

The data indicated that the spray may prevent SARS-CoV-2 infection in the nasal epithelial cells, which are the body’s first point of contact with inhaled allergens and pathogens. It protects these cells by forming a protective layer around them.

Novel prophylactic nasal spray reduced COVID-19 replication by 96% in animal studies

Image credit:

Australian biotech Ena Respiratory has revealed new data demonstrating that its novel nasal spray almost halted replication of the SARS-CoV-2 in animals when used as a prophylactic, showing potential to improve immune response when used alongside COVID-19 vaccines. 

The product, known as INNA-051, is a synthetic small molecule therapy, self-administered once or twice weekly with an almost immediate effect.

European Commission authorises Janssen’s anti-depressant Spravato

The European Commission has approved Janssen’s nasal spray Spravato (esketamine), which is used to treat major depressive disorder (MDD) that has been treatment resistant (TRD).

Bernardo Soares, Medical Director at Janssen UK, said: “We are proud to be introducing this innovative treatment option, which we hope will help to address a significant unmet need.”

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches